Answers are grounded in this paper and cite their sources.
Introduction BIA 28-6156 is an allosteric activator of the beta-glucocerebrosidase enzyme that was investigated to treat people with Parkinson’s with pathogenic variants in the GBA1 gene. Non-clinical data suggest that CYP3A4 is the major metabolizing enzyme of BIA 28-6156, which in turn may act as both an inducer and inhibitor of CYP3A4 and inhibit P-glycoprotein (P-gp)-mediated drug transport. Methods This open- label, fixed-sequence, cross-over, clinical drug-drug interaction (DDI) study enrolled 32 healthy adult participants. In Cohort 1, 16 participants received BIA 28-6156 60 mg orally on Days 1 and 8, and clarithromycin 500 mg twice daily through Days 5–11. In Cohort 2, 16 participants received single doses of dabigatran etexilate 75 mg on Days 1 and 12 and of midazolam 2 mg on Days 2 and 13, and BIA 28-6156 60 mg once daily through Days 4–13. Blood samples were collected for pharmacokinetic (PK) and clinical laboratory tests. PK parameters were derived using non-compartmental methods, while DDI effects were assessed using a mixed-effects model on log-transformed data, which estimated geometric mean ratios (GMR) and 90% confidence intervals (90% CI). Safety/tolerability was evaluated throughout the study. Results Following co-administration with the strong CYP3A4 inhibitor clarithromycin, exposure of BIA 28-6156 increased (GMR of 1.76 [1.68–1.85] for AUC0-t and 1.14 [0.97– 1.35] for Cmax), reinforcing that CYP3A contributes to the metabolism of BIA 28–6156. BIA 28–6156 did not meaningfully affect the PK of midazolam (GMR of 0.98 [0.85–1.13] for AUC0-t, and 1.09 [0.98–1.22] for Cmax), suggesting no clinically relevant effect on CYP3A activity at the evaluated dose. However, BIA 28-6156 increased dabigatran exposure (GMR of 1.58 [1.08–2.31] for AUC0-t, 1.84 [1.40–2.40] for AUC0-inf, and 1.55 [1.04–2.31] for Cmax), consistent with a potential inhibitory effect on P-gp-mediated transport. No serious adverse events or adverse events leading to study discontinuation were reported, and all treatments were generally well tolerated in the studied population. Discussion Together, these findings contribute to the characterization of the clinical DDI profile of BIA 28-6156 and illustrate the clinical evaluation of overlapping victim and perpetrator DDI potential, highlighting the value of characterizing clinically relevant drug interaction mechanisms irrespective of the subsequent development status of a molecule.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: